Allergan Sues Watson, Paddock Over Generic Sanctura

Law360, New York (October 7, 2010, 12:48 PM EDT) -- Allergan Inc. and others have accused Paddock Laboratories Inc. and Watson Pharmaceuticals Inc. of infringing two patents through plans to market generic versions of overactive bladder drug Sanctura XR.

Allergan and Endo Pharmaceuticals Inc. lodged separate complaints Tuesday in the U.S. District Court for the District of Delaware, claiming Paddock and Watson have violated U.S. Patent Numbers 7,781,448 and 7,781,449.

The complaints were filed on behalf of the plaintiffs by William J. Marsden Jr., A. Martina Tyreus, Gregory R. Booker, Jonathan E. Singer, Juanita R. Brooks...
To view the full article, register now.